文献速递神经肿瘤

PHLDB1变异与非功能性垂体腺瘤风险相关

A PHLDB1 variant associated with the nonfunctional pituitary adenoma.
PubMed 文献 · J Neurooncol · 2019-03-13

韩国人群病例对照研究纳入148例非功能性垂体腺瘤患者和375名正常对照,对PHLDB1的27个标签及外显子SNP进行基因分型,发现rs67307131在显性模型下与NFPA风险相关(OR=2.15,95%CI 1.44-3.20;P=0.0002),C/T基因型关联更强(OR=2.39,95%CI 1.60-3.58;P=0.00002)。作者认为PHLDB1遗传变异可能与NFPA风险相关,需进一步研究确认。

要点

  • rs67307131在显性模型下与NFPA风险相关,OR=2.15(95%CI 1.44-3.20;P=0.0002)。
  • C/T基因型患者关联更强,OR=2.39(95%CI 1.60-3.58;P=0.00002)。
  • 该SNP被预测为CpG位点和拷贝数变异,与疾病易感性相关。

核心结论

  • PHLDB1遗传变异可能与NFPA风险相关,这是PHLDB1变异与NFPA关联的首次报告。
  • 需进一步研究确认该SNP对NFPA易感性的影响。

研究设计与样本

  • 病例对照研究,在韩国人群中纳入148例非功能性垂体腺瘤患者和375名正常对照。
  • 对PHLDB1的27个标签及外显子SNP进行基因分型,采用逻辑回归分析SNP与NFPA风险的关联。

主要发现

  • rs67307131位于内含子2,在显性模型下与NFPA显著相关(OR=2.15,95%CI 1.44-3.20;P=0.0002)。
  • 在参考分析中,C/T基因型患者观察到更高的OR和更强的关联(OR=2.39,95%CI 1.60-3.58;P=0.00002)。
  • SNP注释工具功能分析预测该SNP为CpG位点和拷贝数变异,这些特性与疾病易感性相关。

关键数值与推荐

  • rs67307131显性模型:OR=2.15(95%CI 1.44-3.20;P=0.0002)。
  • C/T基因型:OR=2.39(95%CI 1.60-3.58;P=0.00002)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出需进一步研究确认该SNP对NFPA易感性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Previous studies have revealed that PHLDB1 single-nucleotide polymorphisms (SNPs) are associated with glioma risk. Nonetheless, the association between PHLDB1 SNPs and the risk of pituitary adenoma has not been studied. The present study evaluated the association of PHLDB1 SNPs with the risk of pituitary adenomas. METHODS: We genotyped 27 PHLDB1 tagging and exon SNPs in a case-control study that included 148 patients who got a diagnosis of nonfunctional pituitary adenoma (NFPA) and 375 normal controls within the Korean population. Statistical analyses of the association between PHLDB1 SNPs and the NFPA risk were conducted using logistic regression. RESULTS: We detected an association between a PHLDB1 SNP and the risk of NFPA in the Korean population. Rs67307131 in intron 2 was significantly associated with NFPA (odds ratio [OR] = 2.15, 95% confidence interval [CI] 1.44-3.20; P = 0.0002 in the dominant model). In the referent analysis, a higher OR and stronger association (lower P value) were observed among patients with the "C/T" genotype (OR = 2.39, 95% CI 1.60-3.58; P = 0.00002). In a functional analysis with a SNP annotation tool, this SNP was predicted to be a CpG site and copy number variant; these properties are associated with susceptibility to diseases. CONCLUSIONS: Our findings suggest that genetic variation of PHLDB1 may be associated with the risk of NFPA. This is the first report of an association between PHLDB1 variants and NFPA. Further research is needed to confirm the impact of this SNP on NFPA susceptibility.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Kim LH, Kim JH, Namgoong S, et al. A PHLDB1 variant associated with the nonfunctional pituitary adenoma. J Neurooncol. 2019. PMID: 30868356. doi:10.1007/s11060-018-03082-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。